PL361093A1 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL361093A1
PL361093A1 PL01361093A PL36109301A PL361093A1 PL 361093 A1 PL361093 A1 PL 361093A1 PL 01361093 A PL01361093 A PL 01361093A PL 36109301 A PL36109301 A PL 36109301A PL 361093 A1 PL361093 A1 PL 361093A1
Authority
PL
Poland
Prior art keywords
pharmacologically acceptable
pharmaceutical composition
esters
acceptable salts
medicinal compositions
Prior art date
Application number
PL01361093A
Other languages
English (en)
Other versions
PL207252B1 (pl
Inventor
Toshio Sada
Makoto Mizuno
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26604360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL361093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of PL361093A1 publication Critical patent/PL361093A1/pl
Publication of PL207252B1 publication Critical patent/PL207252B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
PL361093A 2000-11-21 2001-11-19 Kompozycja farmaceutyczna zawierająca antagonistę receptorów angiotensyny II, zastosowanie antagonisty receptorów angiotensyny II oraz zastosowanie kompozycji farmaceutycznej zawierającej antagonistę receptorów angiotensyny II PL207252B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000354327 2000-11-21
JP2001164009 2001-05-31
PCT/JP2001/010095 WO2002041890A1 (en) 2000-11-21 2001-11-19 Medicinal compositions

Publications (2)

Publication Number Publication Date
PL361093A1 true PL361093A1 (pl) 2004-09-20
PL207252B1 PL207252B1 (pl) 2010-11-30

Family

ID=26604360

Family Applications (1)

Application Number Title Priority Date Filing Date
PL361093A PL207252B1 (pl) 2000-11-21 2001-11-19 Kompozycja farmaceutyczna zawierająca antagonistę receptorów angiotensyny II, zastosowanie antagonisty receptorów angiotensyny II oraz zastosowanie kompozycji farmaceutycznej zawierającej antagonistę receptorów angiotensyny II

Country Status (23)

Country Link
US (2) US6878703B2 (pl)
EP (2) EP1595540A1 (pl)
KR (1) KR100656716B1 (pl)
CN (1) CN1265788C (pl)
AT (1) ATE324890T1 (pl)
AU (2) AU1432402A (pl)
BR (1) BR0115516A (pl)
CA (1) CA2429260A1 (pl)
CY (1) CY1106134T1 (pl)
CZ (1) CZ20031367A3 (pl)
DE (1) DE60119368T2 (pl)
DK (1) DK1336407T3 (pl)
ES (1) ES2262689T3 (pl)
HU (1) HUP0400553A3 (pl)
IL (2) IL155965A0 (pl)
MX (1) MXPA03004463A (pl)
NO (1) NO332938B1 (pl)
NZ (1) NZ525913A (pl)
PL (1) PL207252B1 (pl)
PT (1) PT1336407E (pl)
SK (1) SK5992003A3 (pl)
TW (1) TWI262076B (pl)
WO (1) WO2002041890A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20070238740A1 (en) 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
JP4511550B2 (ja) * 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
KR20090102883A (ko) * 2004-09-02 2009-09-30 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
AU2006216665A1 (en) 2005-02-24 2006-08-31 Nicox S.A. Nitric oxide enhancing diuretic compounds, compositions and methods of use
KR101314439B1 (ko) * 2005-05-20 2013-10-07 다이이찌 산쿄 가부시키가이샤 덱스트로오스 함유 필름 코팅 제제
WO2006123765A1 (ja) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited フィルムコーティング製剤
WO2007047838A2 (en) * 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Process for preparing olmesartan medoxomil
US8077769B2 (en) * 2006-03-28 2011-12-13 Sony Corporation Method of reducing computations in transform and scaling processes in a digital video encoder using a threshold-based approach
ATE526963T1 (de) * 2006-05-04 2011-10-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit olmesartan- medoxomil
US20100143470A1 (en) * 2006-10-30 2010-06-10 Hanall Pharmaceutical Company, Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
US20100008956A1 (en) * 2008-07-08 2010-01-14 Jie Du Composition and combinations of carboxylic acid losartan in dosage forms
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
WO2019241590A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) 1962-03-13 Reduction of i
US3108097A (en) 1963-10-22 Ehnojs
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US3009911A (en) 1961-11-21 Derivatives of j
US3254076A (en) 1966-05-31 Sulfamyl hydro
US2976289A (en) 1961-03-21 X-tetrahydro -
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
US2835702A (en) 1956-05-02 1958-05-20 Merck & Co Inc Benzene 1, 3 disulfonamides possessing diuretic properties
US2980679A (en) 1957-04-04 1961-04-18 Omikron Gagliardi Societa Di F Process for preparing heterocyclic sulfonamides
US3055904A (en) 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
GB851287A (en) 1958-07-10 1960-10-12 British Drug Houses Ltd 5-chlorotoluene-2:4-disulphonamide and alkali metal salts thereof
US3058882A (en) 1959-12-28 1962-10-16 Hoechst Ag N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
US3255241A (en) 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
GB979994A (en) 1961-07-28 1965-01-06 May & Baker Ltd Isoindolinone derivatives
US3265573A (en) 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
BE639386A (pl) 1962-10-30
DE1278443C2 (de) 1963-11-30 1975-07-24 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,4-disulfonamid-1-chlorbenzolen
US3163645A (en) 1964-09-25 1964-12-29 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2-h-[1, 2, 4]-benzothiadiazine-1, 1-dioxides
DE1270544B (de) 1965-06-19 1968-06-20 Beiersdorf Ag 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung
US3360518A (en) 1966-01-03 1967-12-26 Wallace & Tiernan Inc Tetrahydro-halo-sulfamyl quinazolinones
US3634583A (en) 1969-07-24 1972-01-11 Leo Pharm Prod Ltd Pharmaceutical composition for the treatment of oedematous conditions and hypertension
BE757001A (fr) 1969-10-10 1971-03-16 Cerpha Derives heterocycliques d'acides phenoxy acetique et leur preparation
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0733366B1 (en) * 1988-01-07 1998-04-01 E.I. Du Pont De Nemours And Company Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
IS1756B (is) * 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5310928A (en) 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist

Also Published As

Publication number Publication date
DE60119368D1 (de) 2006-06-08
EP1336407B1 (en) 2006-05-03
HUP0400553A3 (en) 2010-03-29
US6878703B2 (en) 2005-04-12
NO20032261L (no) 2003-07-09
PL207252B1 (pl) 2010-11-30
IL155965A0 (en) 2003-12-23
KR20030096235A (ko) 2003-12-24
CY1106134T1 (el) 2011-06-08
NZ525913A (en) 2004-05-28
CN1486182A (zh) 2004-03-31
NO20032261D0 (no) 2003-05-20
ES2262689T3 (es) 2006-12-01
TWI262076B (en) 2006-09-21
AU2002214324B2 (en) 2004-07-29
US20040002529A1 (en) 2004-01-01
DK1336407T3 (da) 2006-09-04
EP1595540A1 (en) 2005-11-16
MXPA03004463A (es) 2003-08-19
BR0115516A (pt) 2004-02-03
DE60119368T2 (de) 2007-05-03
EP1336407A1 (en) 2003-08-20
IL155965A (en) 2008-08-07
SK5992003A3 (en) 2003-11-04
EP1336407A4 (en) 2004-07-14
CZ20031367A3 (cs) 2003-10-15
AU1432402A (en) 2002-06-03
PT1336407E (pt) 2006-07-31
HK1054692A1 (en) 2003-12-12
CA2429260A1 (en) 2002-05-30
CN1265788C (zh) 2006-07-26
ATE324890T1 (de) 2006-06-15
WO2002041890A1 (en) 2002-05-30
US20050113367A1 (en) 2005-05-26
HUP0400553A2 (hu) 2004-06-28
KR100656716B1 (ko) 2006-12-13
NO332938B1 (no) 2013-02-04

Similar Documents

Publication Publication Date Title
AU1432402A (en) Medicinal compositions
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
MXPA05008142A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
YU68102A (sh) Derivati karboksilne kiseline kao ip antagonisti
BR0206955A (pt) Ligantes de receptores de canabinóides
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
SE9904508D0 (sv) New compounds
WO2003082205A3 (en) Compounds and methods
WO2003049690A3 (en) Hiv integrase inhibitors
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
IL125982A0 (en) 2-(arylphenyl) amino-imidazoline derivatives
EP1750703A4 (en) METHOD FOR REDUCING GASTROINTESTINAL TOXICITY BY ADMINISTRATION OF TEGAFUR
IL122753A0 (en) (R)-5-bromo-n-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridinecarboxamide its preparation and pharmaceutical compositions containing same
WO2002026732A1 (en) Benzodiazepine derivative
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
AU7109798A (en) Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
MXPA04002784A (es) Sales farmaceuticamente aceptables de 20(s)-camptotecinas.
DE60022047D1 (de) Antivirale therapie
ATE270886T1 (de) Antivirale therapie
EP1210948A4 (en) DRUGS FOR NERVOUS DISEASES